- Home
- SOC vs KLTOW Comparison
SOC vs KLTOW Comparison
Compare SOC & KLTOW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOC
- KLTOW
- Stock Information
- Founded
- SOC 2020
- KLTOW N/A
- Country
- SOC United States
- KLTOW United States
- Employees
- SOC N/A
- KLTOW 3
- Industry
- SOC
- KLTOW Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SOC
- KLTOW Health Care
- Exchange
- SOC Nasdaq
- KLTOW Nasdaq
- Market Cap
- SOC 1.8B
- KLTOW N/A
- IPO Year
- SOC N/A
- KLTOW 2022
- Fundamental
- Price
- SOC $5.33
- KLTOW $0.15
- Analyst Decision
- SOC Buy
- KLTOW
- Analyst Count
- SOC 3
- KLTOW 0
- Target Price
- SOC $21.00
- KLTOW N/A
- AVG Volume (30 Days)
- SOC 7.6M
- KLTOW N/A
- Earning Date
- SOC 11-12-2025
- KLTOW N/A
- Dividend Yield
- SOC N/A
- KLTOW N/A
- EPS Growth
- SOC N/A
- KLTOW N/A
- EPS
- SOC N/A
- KLTOW N/A
- Revenue
- SOC N/A
- KLTOW N/A
- Revenue This Year
- SOC N/A
- KLTOW N/A
- Revenue Next Year
- SOC $208.30
- KLTOW N/A
- P/E Ratio
- SOC N/A
- KLTOW N/A
- Revenue Growth
- SOC N/A
- KLTOW N/A
- 52 Week Low
- SOC $4.58
- KLTOW N/A
- 52 Week High
- SOC $35.00
- KLTOW N/A
- Technical
- Relative Strength Index (RSI)
- SOC 22.50
- KLTOW 45.81
- Support Level
- SOC $12.20
- KLTOW $0.13
- Resistance Level
- SOC $13.37
- KLTOW $0.17
- Average True Range (ATR)
- SOC 1.39
- KLTOW 0.02
- MACD
- SOC -0.54
- KLTOW -0.00
- Stochastic Oscillator
- SOC 7.07
- KLTOW 35.81
About SOC Sable Offshore Corp. Common Stock
Sable Offshore Corp is a Houston-based independent upstream company focused on responsibly developing the prolific Santa Ynez Unit in federal waters offshore California. The company is managed as one reportable segment, oil and gas.
About KLTOW Klotho Neurosciences Inc. Warrant
Klotho Neurosciences Inc is in the development of essential medicines for the treatment of chronic diseases: Cancer, Cardiovascular, and Neurodegenerative disorders. The Company currently has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Company pipeline includes KLTO 101, KLTO 202, KLTO 301.